Last verified: April 2026

Receptor Pharmacology: Partial Agonism and Its Consequences

Δ⁹-THC was isolated and synthesized by Raphael Mechoulam and Yechiel Gaoni at the Weizmann Institute in 1964. At the CB1 receptor, THC acts as a partial agonist with a binding affinity (Ki) of approximately 6.62–40.7 nM, depending on the assay system and tissue preparation. The “partial” designation is pharmacologically critical: unlike a full agonist, which produces maximal receptor activation, a partial agonist can only achieve a fraction of the receptor’s maximum signaling capacity, regardless of dose.

This partial agonism has two important implications. First, it establishes a ceiling effect — there is a maximum level of CB1 activation that THC can produce, no matter how much is consumed. This contributes to cannabis’s remarkably wide therapeutic index. Second, in the presence of a full agonist (such as the endocannabinoid 2-AG), a partial agonist can act as a functional antagonist by competing for receptor binding while producing less activation — a phenomenon that may partially explain why chronic heavy cannabis use can paradoxically reduce endocannabinoid signaling efficiency.

At the CB2 receptor, THC also acts as a partial agonist with lower affinity than at CB1. This CB2 activity contributes to THC’s immunomodulatory and anti-inflammatory effects, though these are less well characterized clinically than its CNS effects.

The Biphasic Dose-Response: Why Dose Is Everything

Perhaps the most underappreciated aspect of THC pharmacology is its biphasic dose-response relationship, particularly with respect to anxiety. In a landmark 2017 study published in Drug and Alcohol Dependence, Emma Childs and colleagues at the University of Chicago tested 42 healthy volunteers in a double-blind, placebo-controlled design with two THC doses:

• 7.5 mg THC (low dose): subjects reported reduced negative emotional responses to a standardized psychosocial stress task (the Trier Social Stress Test), decreased self-reported distress, and increased positive affect
• 12.5 mg THC (moderate dose): subjects reported increased negative emotional responses, greater anxiety and dysphoria, and reduced positive affect during the same stress task

A mere 5 mg difference reversed the direction of the effect. This is not a subtle finding — it demonstrates that THC is anxiolytic at low doses and anxiogenic at higher doses, with a narrow window between the two.

Aarón Avendaño Rey and colleagues (2012) proposed a mechanistic explanation: at low concentrations, THC preferentially modulates cortical glutamatergic circuits (producing anxiolysis through reduced excitatory drive), while at higher concentrations it additionally engages GABAergic interneurons, reducing inhibitory tone and unmasking anxiety-promoting circuits. The specifics of this model remain debated, but the biphasic phenomenon itself is one of the most consistently replicated findings in cannabinoid pharmacology.

The Dopamine Story: Not What You Think

THC’s rewarding and potentially addictive properties involve dopamine signaling, but the mechanism is indirect and substantially different from stimulants or opioids. THC does not directly stimulate dopamine release. Instead, it activates CB1 receptors on GABAergic interneurons in the ventral tegmental area (VTA). These interneurons normally exert tonic inhibition on dopaminergic projection neurons. By suppressing GABA release from these interneurons (a process called disinhibition), THC effectively removes the brake on dopamine neurons, allowing increased dopamine release into the nucleus accumbens.

This disinhibition mechanism is important for several reasons. It is less robust than the direct dopamine release produced by cocaine or amphetamine, which helps explain why cannabis has lower addiction potential (though cannabis use disorder is real and affects approximately 9% of users). The magnitude of dopamine release is modest — typically 25–50% above baseline in animal models, compared to 200–400% for cocaine. This is consistent with clinical observations: cannabis produces reinforcement but rarely the compulsive, escalating use patterns characteristic of stimulant addiction.

Metabolism: Why Edibles Hit Different

THC metabolism explains one of the most clinically relevant phenomena in cannabis pharmacology: the markedly different experience between inhaled and orally consumed cannabis. When THC is inhaled, it passes directly from the lungs into the arterial circulation, reaching the brain within seconds. Peak plasma concentrations occur within 3–10 minutes, and psychoactive effects begin almost immediately.

Oral consumption follows a fundamentally different pathway. THC is absorbed from the GI tract and transported via the portal vein to the liver, where it undergoes extensive first-pass metabolism by cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4. The principal phase I metabolite is 11-hydroxy-THC (11-OH-THC), which is itself pharmacologically active — and significantly more potent than THC:

• 11-OH-THC is estimated to be 1.5 to 7 times more potent than Δ⁹-THC at CB1, depending on the assay
• 11-OH-THC crosses the blood-brain barrier more readily than THC due to its greater hydrophilicity
• Oral consumption produces higher 11-OH-THC:THC ratios than inhalation, because first-pass hepatic metabolism converts a larger proportion of THC before it reaches systemic circulation

This is why edibles produce a qualitatively different — and frequently more intense — experience than smoked cannabis, even at nominally equivalent THC doses. Onset is delayed (30–120 minutes), peak effects are prolonged (4–8 hours vs. 1–3 hours for inhalation), and the higher 11-OH-THC exposure can produce anxiety, dysphoria, and paranoia in cannabis-naive individuals. Emergency department presentations related to cannabis edibles increased substantially following legalization in Colorado, Washington, and other early-legal states.

The terminal metabolite, 11-nor-9-carboxy-THC (THC-COOH), is pharmacologically inactive — it does not bind CB1 or produce psychoactive effects. However, it is the analyte detected by standard urine drug tests. THC-COOH is highly lipophilic and accumulates in adipose tissue, producing positive urine tests for days to weeks after last use in regular consumers. This means urine testing detects prior exposure, not current impairment — a distinction with significant legal and occupational implications.

Therapeutic Index and Safety Profile

THC’s therapeutic index — the ratio between the lethal dose and the therapeutic dose — is estimated at approximately 1:20,000 to 1:40,000. For context:

• Opioids (morphine): approximately 1:6
• Alcohol (ethanol): approximately 1:10
• Aspirin: approximately 1:20
• THC: approximately 1:20,000–40,000

This extraordinary safety margin is a direct consequence of the near-absence of CB1 receptors in brainstem cardiorespiratory centers. A human would need to consume approximately 680 kg of cannabis in 15 minutes to reach the LD50 extrapolated from animal data — a physical impossibility. No confirmed human death from THC pharmacological toxicity alone has been documented.

However, the therapeutic index addresses only acute lethality. Cannabis is not “safe” in any absolute sense. Well-documented acute risks include tachycardia (20–50 bpm increase), orthostatic hypotension, acute psychosis (especially in predisposed individuals), severe anxiety, and impaired driving. Chronic risks include cannabis use disorder (~9% of users, ~17% of adolescent-onset users), potential acceleration of psychotic disorders in genetically vulnerable individuals, and chronic bronchitis with smoked consumption.

FDA-Approved THC Pharmaceuticals

THC has been available as an FDA-approved pharmaceutical since the 1980s:

• Dronabinol (Marinol) — synthetic Δ⁹-THC in sesame oil capsules. First approved in 1985 for chemotherapy-induced nausea and vomiting (CINV), then expanded in 1992 to include AIDS-associated anorexia and weight loss. Generic formulations are now available. Dronabinol demonstrates the clinical utility of THC for specific, well-defined indications
• Nabilone (Cesamet) — a synthetic THC analog (not identical to plant-derived THC). Originally approved in 1985, reintroduced in 2006 for CINV refractory to conventional antiemetics. Nabilone has slightly different receptor binding kinetics than THC but produces similar clinical effects

Both dronabinol and nabilone are Schedule III controlled substances in the United States, while whole-plant cannabis remains Schedule I — an inconsistency that has been widely noted and that played a role in the DEA’s rescheduling deliberations.

The biphasic effect of THC on anxiety is one of the most reliable findings in human cannabinoid research. The difference between an anxiolytic and an anxiogenic dose can be as small as 5 milligrams.

Emma Childs et al., Drug and Alcohol Dependence, 2017